Status:
UNKNOWN
Neurosarcoidosis : Initial Presentation and Disease Course
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Neurosarcoidosis
Eligibility:
All Genders
Brief Summary
Neurosarcoidosis represents up to 10% of sarcoidosis cases. Little is known about its long-term course, even if the disease remains mainly monophasic with/w.o. sequelae, or if bouts of new symptoms ma...
Detailed Description
Sarcoidosis is a systemic inflammatory disease which a 10-20/100.000/year incidence rate. The nervous system is found to be affected in 5-10% in clinical series, rising to 14-27% in post-mortem studie...
Eligibility Criteria
Inclusion
- To have at least one documented visit in one of the three referral neurological centers (Nancy, Bordeaux, Strasbourg) between Jan-1st-2000 and Jan-1st-2021
- To be diagnosed with possible/probable/definite neurosarcoidosis
Exclusion
- \- Denial to participate to the study
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04911348
Start Date
June 1 2021
End Date
August 1 2021
Last Update
June 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guillaume Mathey
Nancy, Lorraine, France, 54000